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Abstract
Mendelian randomization (MR) studies typically assess the pathogenic relevance of en-
vironmental exposures or disease biomarkers, using genetic variants that instrument
these exposures. The approach is gaining popularity—our systematic review reveals a
greater than 10-fold increase in MR studies published between 2004 and 2015. When the
MR paradigm was first proposed, few biomarker- or exposure-related genetic variants
were known, most having been identified by candidate gene studies. However, genome-
wide association studies (GWAS) are now providing a rich source of potential instru-
ments for MR analysis. Many early reviews covering the concept, applications and
analytical aspects of the MR technique preceded the surge in GWAS, and thus the ques-
tion of how best to select instruments for MR studies from the now extensive pool of
available variants has received insufficient attention. Here we focus on the most common
category of MR studies—those concerning disease biomarkers. We consider how the se-
lection of instruments for MR analysis from GWAS requires consideration of: the
assumptions underlying the MR approach; the biology of the biomarker; the genome-
wide distribution, frequency and effect size of biomarker-associated variants (the genetic
VC The Author 2016. Published by Oxford University Press on behalf of the International Epidemiological Association. 1600
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
International Journal of Epidemiology, 2016, 1600–1616
doi: 10.1093/ije/dyw088
Advance Access Publication Date: 24 June 2016
Original article
architecture); and the specificity of the genetic associations. Based on this, we develop
guidance that may help investigators to plan and readers interpret MR studies.
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Introduction
Adverse environmental influences, such as smoking and al-
cohol consumption, are associated with a higher risk of
many chronic, non-communicable diseases. Individuals at
higher risk also exhibit alterations in numerous quantita-
tive biological traits (also known as disease biomarkers or
intermediate phenotypes), years before disease onset
(Supplementary Table 1, available as Supplementary data
at IJE online). These associations have been identified
mainly through non-genetic observational studies.
However, observational epidemiological studies of this
type can be subject to a variety of biases. Importantly, it
can be difficult to separate causal associations from those
that arise from confounding or reverse causation. Effect es-
timates from such studies may also be prone to regression
dilution bias1 and errors in the measurement of the bio-
marker for technical or biological reasons.1
Mendelian randomization (MR) is an evolving para-
digm in which genetic variants (usually single nucleotide
polymorphisms, SNPs) are used to help distinguish causal
from non-causal associations between environmental ex-
posures or biomarkers and disease outcomes.2 Two unique
attributes of genotype make this possible. First, the ran-
dom allocation of parental alleles to zygotes at meiosis, in-
dependent of environmental exposures, reduces the
potential for confounding in genetic association studies in
the same way as randomized treatment allocation in clin-
ical trials3,4 (Figure 1a). Second, the invariant nature of the
DNA sequence and unidirectional flow of biological infor-
mation, from gene sequence through intermediate pheno-
types to disease, avoids reverse causation, though it should
not be taken to imply a stability of genetic effect which in
theory could be modified in a context-dependent fashion.5
An MR study typically considers three types of associ-
ation: (i) the association of a biomarker (or environmental
exposure) with the disease outcome; (ii) the association of
a genetic variant with biomarker or environmental expos-
ure; and (iii) the association of the same variant with dis-
ease risk6 (Figure 1b). Provided certain assumptions are
met (Figure 1), consistency in direction and magnitude of
the three estimates provides evidence on causal relevance
of the environmental exposure or biomarker. The causal
effect can be quantified within a formal statistical frame-
work, using instrumental variables methods which have
been adopted and adapted from the econometric litera-
ture.7,8 Some illustrative examples of the early use of MR
are outlined in Box 1 and Table 1, and more recent ex-
amples that have exploited certain enhancements to the
MR approach, are described in more detail later in this. It
is notable that several important MR studies of certain dis-
ease biomarkers have identified inconsistency between ef-
fect estimates obtained in non-genetic observational
studies and those through MR analysis that have altered
thinking on the causal relevance of those biomarkers, as
we describe later.
A systematic review (see Supplementary methods for de-
tails, available as Supplementary data at IJE online) reveals
a 10-fold increase in MR studies published between 2004
and 2015 (Supplementary Figure 1, available as
Supplementary data at IJE online). The majority have been
in the fields of cardiovascular disease and diabetes (51% of
published studies); other disease areas including cancer
Key Messages
• MR offers novel opportunities for reliable causal inference within the framework of observational research designs.
• The findings from an MR analysis can provide insight into the pathophysiology of complex disease and have transla-
tional relevance, including the prioritization of drug targets.
• The emerging genetic architecture of disease biomarkers now allows more informed selection of genetic variants for
MR studies than was hitherto possible.
• As the number of biomarker-associated variants grows though genome-wide association studies and, more recently,
metabolomics and proteomics, selection of the most appropriate instruments for MR analysis will become an increas-
ingly important issue.
• We have proposed a set of principles that should inform the selection process to aid the design, analysis and inter-
pretation of MR studies.
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(10%); and mental health (10%). Most MR studies (86%)
have been of disease biomarkers (defined in Box 2) such as
blood lipids, body mass index (BMI) or blood pressure, and
50% have used a candidate gene approach to identify suit-
able instruments (Table 1). However, genome-wide associ-
ation studies (GWAS) of disease biomarkers are providing a
new source of instruments for MR analysis. Of the 2111
GWAS listed in the NIH National Human Genome
Research Institute (NHGRI) GWAS catalogue9,10 [http://
www.genome.gov/gwastudies, as of 23 August 2015], 672
(32%) concern genetic variants associated with 520 disease
biomarkers, with some variants exhibiting associations with
more than one biomarker. Other studies based on high-
density locus-centric SNP arrays such as Metabochip11 and
Immunochip12, designed based on GWAS findings in cardi-
ometabolic and autoimmune/inflammatory disorders
respectively, have reported many additional genotype-
biomarker associations. Many MR studies (n ¼ 211) were
published after a GWAS of their corresponding biomarker;
of those studies, 61% (n ¼ 129) used the preceding GWAS
to inform the selection of the instruments.
Many of the early reviews in the field that covered the
concept, applications1,2,7,13–15 and analytical aspects of the
MR technique16–18 preceded the surge of GWAS. Thus, the
question of how best to select instruments for MR studies,
given the now extensive pool of available variants, has
received insufficient attention. In this article we focus on
the most common category of MR studies—those concern-
ing disease biomarkers (see Box 2). We show that using
GWAS as a source of instruments for MR analysis requires
consideration of the assumptions underlying the MR ap-
proach, the biological nature of the biomarker of interest,
the distribution of SNP-biomarker associations at the gen-
ome-wide and regional levels, the genetic effect sizes and
specificity of associations.
Figure 1. A: Mendelian randomization is a natural analogue of the clas-
sical randomized controlled trial (RCT). Random allocation of alleles
at conception and the unidirectional flow of information from
DNA sequence to endogenous biomarker phenotype allow causal infer-
ence of the type possible within the RCT framework. Genotype is gener-
ally unrelated to environmental exposures, thus reducing confounding.
B: the Mendelian randomization model: the causal role of an exposure,
P, on a disease state, D, is being evaluated. A genetic variant, G, is asso-
ciated with biomarker P but not with confounders, U. Variant G is also
associated with disease D and acts only through its effects on bio-
marker P. The model rests on three core assumptions: (i) the genetic
instrument (G) is associated with the exposure or biomarker of interest
(P); (ii) the genetic instrument (G) is independent of potential confound-
ing factors (U) in the relationship between the exposure/biomarker (P)
and the outcome (D); (iii) the outcome (D) is associated with the genetic
instrument (G) only through the effect of the exposure/biomarker (P),
and is in all other respects independent.
BOX 1. Applications of Mendelian randomization
MR analysis has been applied to assess whether CRP, a circulating marker of inflammation, plays a true causal role in
the development of CHD. Despite the robust association of CRP level with CHD in observational studies, CRP variants
used to instrument long-term elevations in CRP concentration did not provide evidence of a causal role for this bio-
marker in the development of CHD, based on meta-analysis of up to 47 studies including 46 557 cases.78,82,125 The
observational association between CRP and CHD is more likely explained by confounding or reverse causation. HDL-
cholesterol (HDL-C) exhibits an inverse association with CHD risk in observational studies, but whether this association
is causal has been in dispute. An MR study used variants in the LIPG gene, encoding hepatic lipase, as an instrument
for HDL-C and examined its relationship with myocardial infarction (MI) risk.104 Although higher HDL-C is observation-
ally associated with lower MI risk, MR analysis based on LIPG variants, both alone and within allele scores to instru-
ment HDL-C concentration, did not find evidence for a causal role for HDL-cholesterol in CHD.
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Assumptions underlying MR analysis
The MR approach, as classically described, rests on the
assumption that any disease association of a genetic vari-
ant employed as an instrument because it proxies the bio-
marker of interest should be both unconfounded and
explained exclusively through an effect on the biomarker
(Figure 1b).15 A potential violation of these assumptions
occurs when an SNP associates with several biomarkers,
only one of which is of causal interest. The association of
a genetic variant with more than one phenotype is
commonly referred to as pleiotropy. When pleiotropy is
observed, two of the three critical assumptions of an MR
analysis may be called into question. However, as we
show later, a pleiotropic variant need not necessarily be
excluded as an instrument, provided careful consideration
is given to the mechanism giving rise to the pleiotropy
and to the nature of the biomarker of interest; specific-
ally, whether or not this is a protein. We also evaluate a
number of enhancements to the basic MR design, based
on multiple instruments which have since been developed
partly to enhance power of MR studies, and partly to
overcome some of the challenges imposed by pleiotropic
instruments.
Disease biomarkers and their position in the
putative disease pathway
Interest in some disease biomarkers is in their performance
as predictors of disease risk.1 For this application, it is not
essential that the biomarker-disease association is causal;
merely that there is a demonstrable and consistent associ-
ation of the biomarker with the disease, that is of sufficient
magnitude to make it a useful predictor. However, if there
is interest in the potential aetiological role of a biomarker
that might be amenable to modification by public health
measures or drug treatment, evidence on a causal associ-
ation is essential. Thus, reliable demonstration of even a
modest causal effect through genetic association analysis
could still be important because of the potential to develop
interventions with a much larger effect on the same
biomarker.2,16
Disease biomarkers are biologically diverse, encompass-
ing circulating proteins (e.g. fibrinogen, C-reactive protein
or interleukin-6), low molecular weight metabolic inter-
mediates (e.g. homocysteine and uric acid) and complex
physiological phenotypes such as blood pressure
(Supplementary Table 1). Most biomarkers are continuous
traits with genetic and environmental determinants. Many
follow an approximately normal (or log-normal) distribu-
tion, and show a linear (or log-linear) association with dis-
ease risk. As we show later in a detailed discussion of
potential reasons for genetic pleiotropy, the position of the
biomarker of interest in the pathway connecting genetic
variation to disease risk has an important bearing on the
design, interpretation and validity of an MR study. In par-
ticular, we show why MR analysis of protein biomarkers
instrumented by SNPs in the encoding gene has certain ad-
vantages over other categories of MR analysis.
Genetic architecture of SNP-biomarker
associations
The wealth of GWAS findings allows some observations to
be made about the genetic architecture of different disease
biomarkers, which has bearing on the selection of SNPs for
MR analysis of these traits. However, it must be borne in
mind that most previous GWAS have utilized genotyping
arrays that have a bias towards common variants, so that
there is less information on alleles of lower frequency and
their potential role as instruments in MR analysis.
C-reactive protein (CRP), an acute-phase protein associ-
ated in observational studies with cardiovascular disease
(CVD) risk, provides an illustrative example (Box 1).
BOX 2. A hierarchy of biomarkers for Mendelian randomization studies based on the central dogma
For the purposes of this review, we separate exposures that might alter disease risk that are external (exogenous) to
the body (e.g. cigarette smoke or socioeconomic position) from those that are internal to the body (endogenous), which
we refer to as disease biomarkers. We recognize a hierarchy of disease biomarkers that reflects the central dogma—the
unidirectional information flow from gene through mRNA to protein. The influence of genetic variation is initially on
mRNA sequence or level, and then on the function or amount of the encoded protein. Such alterations in proteins then
lead to the downstream biochemical or structural alterations, including changes in more complex phenotypes (e.g.
blood pressure) that affect disease risk. Among these endogenous exposures, we draw a natural distinction between
proteins and more downstream biomarkers because proteins usually represent products of individual genes and are
the most proximal, widely measured consequence of natural genetic variation (Figure 2).
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Three ‘Manhattan’ plots (Supplementary Figure 2, avail-
able as Supplementary data at IJE online) depict genetic as-
sociations with CRP: the first is based on findings in 5000
participants from the Whitehall II study,19 genotyped using
a gene-centric 50000 -SNP array (IBC HumanCVD
BeadChip ‘Cardiochip’) covering 2100 genes implicated in
CVD;20 the second is from a GWAS in 6345 participants
from the Women’s Genome Health Study;21 and the third
is from a subsequent meta-analysis of GWAS of CRP
including 82 725 participants from 15 studies.22 The find-
ings illustrate some general features of genomic associ-
ations with biomarkers.
First, genetic associations with mRNA expression or
protein biomarkers such as CRP may be detected with
smaller sample sizes when compared with studies of dis-
ease endpoints, presumably because the level or function of
a protein biomarker is a comparatively proximal conse-
quence of genetic variation, with fewer biological steps be-
tween DNA sequence variation and protein synthesis and a
larger signal-to-noise ratio.23 For more distal biomarkers
such as blood metabolites or complex physiological pheno-
types such as blood pressure, larger samples have typically
been required. Nevertheless, regardless of the type of bio-
marker, increasing sample size, usually through meta-
analysis, leads to identification of additional associated
variants. Low-frequency variants, such as those identified
by newer exome and whole genome sequencing studies
sometimes of larger effect than common variants studied in
GWAS, but common alleles can also on occasion produce
large effect sizes. However, whole genome arrays are
mainly populated by common alleles and even imputation
against the 1000 Genomes reference panel most efficiently
captures information on other common rather than rare al-
leles. Therefore, the new loci detected later in larger
GWAS datasets tend to also harbour common variants but
with smaller effects than the loci identified by earlier,
smaller studies. For example, when 25 independent GWAS
of CRP were pooled by meta-analysis, with an aggregate
sample of 82 725 individuals, 12 additional loci were iden-
tified beyond the 7 reported by an earlier, smaller study.
The effect sizes at each of these new loci were generally
smaller than in the sentinel study (Supplementary Figure 3,
available as Supplementary data at IJE online).22 Meta-
analyses of GWAS of blood lipids,24 BMI,25 blood pres-
sure26 and other disease biomarkers have also led to the
identification of new loci also generally of smaller pheno-
typic effect, undetected by earlier, smaller GWAS.
Second, loci containing genetic variants associated with
CRP are scattered throughout the genome. This appears to
be a general feature of loci associated with disease bio-
markers, such as circulating metabolites (e.g. homocyst-
eine27 and uric acid28,29), lipoproteins,30–32 metabolomic
profiles33–36 and the more complex physiological pheno-
types such as blood pressure26,37,38 and BMI.25,39–46 For
protein biomarkers like CRP, a natural and important dis-
tinction emerges between two categories of genetic variants
that might be used for MR analysis. The first are those
variants acting in cis, located in the vicinity of the encoding
gene (in this case CRP, chr1q23.2), which are potentially
coincident with cis-eQTLs (expression quantitative trait
loci) influencing mRNA expression. GWAS of mRNA ex-
pression profiles and protein biomarker concentrations in-
dicate that cis-acting variants are a common feature of the
genome.47 The second category contains those acting in
trans, i.e. located outside the gene encoding the protein
biomarker of interest, often on a different chromosome.
A variant at one locus associated with an effect on expres-
sion of a distant gene may operate via chromosomal con-
formational mechanisms, through microRNAs that alter
mRNA stability of a range of distant target genes,48 or be-
cause they are located in genes encoding transcription fac-
tors that regulate expression of other physically distant
genes49 or by downstream biochemical mechanisms. It is
SNPs of this type that can often be pleiotropic.
Third, it is typical not only to identify associations with
biomarkers at widely separated genomic locations, but
also to observe multiple biomarker-associated SNPs at
each locus. Although multiple independent causal variants
may be present at a single locus, the multiplicity of associ-
ations commonly arises due to linkage disequilibrium (LD)
between SNPs, only a subset or one of which may be func-
tional. In order to use a SNP as an instrument in MR ana-
lyses, it is not necessary to prove the SNP itself is the
causal variant, provided that its association with the bio-
marker of interest arises from LD with a causal variant
within the same locus. Moreover, and importantly, there
must be no additional LD with other nearby variants that
might influence the expression or activity of a different
protein. Were that the case, LD would lead to confounding
and violate a key assumption of the MR paradigm. Both
local LD (i.e. in the immediate vicinity of a given SNP) and
distant LD (i.e. elsewhere on the same chromosome) can
be ascertained using web-based tools such as the SNP
Association and Proxy Search (SNAP) resource at [http://
www.broadinstitute.org/mpg/snap/50]. In the CRP ex-
ample, the CRP gene51–55 is isolated by two recombination
hotspots (Supplementary Figure 4a, available as
Supplementary data at IJE online) with no evidence for LD
with SNPs in the adjacent DUSP23 and APCS genes. This
substantially reduces the risk that confounding by LD
would compromise MR analysis using SNPs in the CRP
gene. SNP selection for an MR analysis becomes more
challenging where multiple SNPs are in LD, all associate
with the biomarker of interest and the associations span
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several genes in close physical proximity. For example, a
74kb region of chromosome 1 (chr1p36.2) contains the
MTHFR, NPPA and NPPB genes and includes SNPs asso-
ciated with circulating concentrations of homocysteine,
atrial- and brain–type natriuretic peptide, each of which
have been implicated as causal factors in cardiovascular
disease56–58 (Supplementary Figure 4b). Statistical methods
for prioritizing SNPs in such circumstances, such as condi-
tional analysis or variable selection, are available and have
been described elsewhere.59,60 Recent developments in-
clude a Bayesian statistical test to quantify the probability
that associations observed at the same locus with a range
of outcomes (e.g. mRNA expression, blood a biomarker
disease outcome) can be explained by the same causal vari-
ant,61 which may help map association signals from a
GWAS to the responsible gene. However, functional anno-
tations or experimental evidence may be required in some
cases to support the selection of instruments.
Genetic effect size
SNP arrays deployed in GWAS contain common variants
(minor allele frequency, MAF, > 5%), which tend to have
small to moderate effect sizes.62 Statistical analyses in
GWAS set stringent significance thresholds (typically
P-value < 5 x 10-8) in order to reduce the number of false-
positive associations arising from the vast number of
statistical tests performed. For this reason, and because
false-positive associations were a feature of the era of can-
didate gene association studies,63 much attention in a
GWAS is correctly on the reliability of any genetic associ-
ation, based on the P-value.
Provided an association is identified robustly, the size of
the genetic effect gains importance when prioritizing SNPs
for use as MR instruments, with SNPs of larger effect pre-
ferred because they increase statistical power provided the
minor allele frequency is sufficiently high.7 In a study with
a fixed sample size, the P-value for the SNP-biomarker as-
sociation provides an indirect measure of the effect size,
but this is also influenced by the frequency at which the
variant occurs in the sample, and the LD relationship be-
tween the typed variant and the causal variant (if they
differ).
Specific metrics of effect size can be used to inform the
selection of SNPs as instruments in an MR analysis. The
most commonly used indicators of effect are: (i) the beta-
coefficient from a linear regression of each additional
minor allele of an SNP locus with the trait of interest,
which equates to the absolute difference in concentration
of biomarker for each additional allele, expressed on the
native or standardized scale; (ii) the proportion of the
phenotypic variance explained by the SNP in the sample
(R2); and (iii) the F-statistic from the linear regression
model of the genetic instrument with the biomarker. Both
R2 and the F-statistic are influenced by the minor allele fre-
quency, and the F-statistic is additionally affected by the
sample size,64 For the F-statistic, an arbitrary threshold
value of F > 10 has been proposed for determining suit-
ability of SNPs for MR analysis,7 to avoid weak-instru-
ment bias. However, investigators should be cautious
about the use of an arbitrary F-statistic threshold for the
selection of instruments, particularly where the estimate of
the F-statistic comes from a single small study. As reported
by Burgess and Thompson,65 F-statistic estimates can be
inflated by chance in small studies. This is because ‘con-
founders may not be perfectly balanced between genotypic
subgroups in finite samples’.65 Under such circumstances
the chance difference in confounders may explain more of
the difference in the biomarker of interest between the
genotypic groups than the instrument itself. As a corollary,
the estimate of the causal association will be inflated to-
wards that of the biased observational association between
the biomarker and disease outcome. Since the F-statistic is
related to the proportion of the variance in the biomarker
explained by the genetic variants, the sample size and the
number of instruments, Burgess and Thompson suggest
three ways in which this effect can be mitigated: by increas-
ing the sample size and/or by combining genotype bio-
marker associations across studies by meta-analysis; by
increasing the number of instruments; and by adjusting for
measured covariates. Many of these approaches are now
routinely applied in contemporary MR analysis
Returning to the CRP example, Supplementary Figure 5
(available as Supplementary data at IJE online) illustrates
how the choice of effect metric affects the ranking of po-
tential SNPs that might be used as instruments in an MR
analysis. In general, low-frequency variants with large ef-
fects tend to rank highly when assessed using the beta-
coefficient, but diminish in priority when ranked by the
proportion of variance explained (R2) or F-statistic, be-
cause the latter penalize low allele frequency. In general,
we have found the proportion of variance explained (R2)
to be the most useful metric of effect when planning SNP
selection for MR analysis. For these reasons, most success-
ful MR analyses to date have relied mainly on common
variants as instruments. Rare variants are of value in other
types of study design, including recall-by-genotype studies.
Though common SNPs typically explain only a small
proportion of the variance in a trait, the value of R2 should
be placed in context. For example, a common SNP
(rs1205) in the vicinity of the CRP gene (MAF ¼ 0.34)
explains only 0.7% of the variance in this trait, but the
difference in CRP concentration per allele (beta-coefficient:
-0.15mg/l log CRP) is similar in magnitude to the
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difference in CRP value between treatment and control
groups in a randomized clinical trial of rosuvastatin, a po-
tent statin drug which lowers CRP in addition to its effect
on blood lipids.66
The degree to which loci contribute to biomarker vari-
ance may also vary. For some biomarkers, a single locus
may dominate (e.g. LPA associated with lipoprotein(a)
concentration).67,68 In other cases, gene-centric and gen-
ome-wide analyses of uric acid29 and HDL-
cholesterol31,32,69–71 indicate that SNPs at multiple loci
contribute to the variance in each trait but certain loci har-
bour variants of large effect [SLC2A9 and CETP, respect-
ively, (Supplementary Figure 6, available as Supplementary
data at IJE online)]. In our experience, SNPs acting in cis
with effects on mRNA transcription level and protein con-
centration are often, but not invariably, those with the
largest effect21.
Specificity of the genetic association
The assortment of alleles at the time of gamete formation
is independent of environmental factors. This is why gen-
etic variants associated with disease biomarkers generally
exhibit no association with behavioural, dietary and life-
style factors, even though the biomarkers they instrument
frequently do.72 However, we note that certain genetic
variants have been identified that influence habitual behav-
iours such alcohol and coffee consumption or
smoking.73–75 In such cases, these associations arise not be-
cause of non-random assortment, but rather because there
is a mechanistic explanation: the variants influence the ex-
pression or function of genes involved in the handling of,
or response to, chemical constituents of these exposures
leading to an alteration in smoking or drinking behaviour.
Such variants have in fact served as useful instruments to
evaluate the causal influence of such exposures on the risk
of common disease76,77 (Table 1).
A previous MR analysis of CRP (Box 1) using cis-acting
SNPs in the CRP gene as instruments, had a particularly
straightforward interpretation because variants in the gene
were associated exclusively with the encoded CRP protein
but none of the very wide range of other biomarkers with
which CRP itself is associated.78 Similarly, specific geno-
type-biomarker associations were reported in an MR ana-
lysis of fibrinogen levels using SNPs in the FGB gene
related to fibrinogen levels.79 However, because of the
complex biological inter-relationships between the widely
measured circulating biomarkers,80 biomarker-associated
SNPs rarely exhibit the degree of specificity that was for-
tuitously observed with SNPs in the CRP gene; it is more
common to find that SNPs identified for an association
with one biomarker are also associated with several others.
Speculatively, this issue is likely to become more prominent
as a wider range of biomarkers are more routinely meas-
ured using new proteomic and metabolomic technologies.
For example, variants in LIPC (rs4775041, chr15q21.3)
are associated with both HDL-cholesterol and triglycer-
ides,81 and variants at the APOE cluster (rs4420638,
chr19q13.32) with LDL-cholesterol, HDL-cholesterol, tri-
glycerides,69 CRP,82 Lp(a) levels83 and lipoprotein-associ-
ated phospholipase A2 activity.84 At first glance, this lack of
specificity might be interpreted as irrevocably violating one
of the principal assumptions of the MR paradigm. For ex-
ample, an association of the rs662799 SNP in the APOA5
gene (chr11q23.3) with triglyceride level and coronary heart
disease (CHD) risk85 may be taken to indicate a causal role
in CHD for triglycerides. However, since this SNP is also
associated with HDL-cholesterol, it is uncertain whether the
CHD association of this SNP reflects its effect on triglycer-
ides, HDL-cholesterol or some other consequence of vari-
ation in this gene.
The mechanisms responsible for pleiotropy may be var-
ied, but have been incompletely characterized. However,
based on available understanding of genomic organization
and gene regulation, established or theoretical reasons for
an association of a SNP with several biomarkers include
(Figure 2):
i. an effect on expression of an alternatively spliced gene
leading to two distinct protein products with different
actions (Figure 2a);
ii. linkage disequilibrium between SNPs spanning nearby
genes at the same locus (i.e. the problem of confound-
ing by LD) (Figure 2b);
iii. an effect in cis on expression and in trans (either
directly or through LD with an adjacent SNP) on a
physically distant gene mediated through chromo-
somal conformational effects (Figure 2c);
iv. an effect on expression of a microRNA that regulates
the stability of transcripts from multiple target genes
(Figure 2d);
v. an effect on expression of a transcription factor (e.g.
hepatocyte nuclear factor-1a86) that regulates several
distant target genes (Figure 2e);
vi. and residency of an SNP in a gene encoding a single
protein whose activity influences several downstream
biomarkers, some of which lie on the causal pathway
to a disease outcome and some which may not
(Figure 2f, g).
Two assumptions of an MR analysis are that the instru-
ment should not be associated with any confounder of the
biomarker disease association and that the association of
the genetic instrument with the disease outcome should be
mediated solely through the biomarker of interest. When a
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genetic variant is associated with several biomarkers,
including the biomarker of interest, the assumptions of an
MR analysis will be violated if the explanation for the plei-
otropy is a disease pathway that branches more proximally
to the biomarker of interest. This has been termed horizon-
tal pleiotropy.87 By contrast, the assumptions of an MR
analysis hold if the associations of a genetic variant with
several biomarkers arise because of the serial and sequen-
tial effects of the biomarker of interest on others residing
more distally on the same causal pathway to disease. This
has been termed vertical pleiotropy. In Figure 2, we ex-
plain in more detail how the different established and puta-
tive mechanisms listed above could give rise either to
horizontal or vertical pleiotropy, and the implications for
MR analysis.
Thus, when faced with a candidate instrument that ex-
hibits genetic pleiotropy, a critical issue for MR analysis is
the likelihood that this is vertical rather than horizontal in
nature. Confidence in a vertical explanation for pleiotropy
may be high when there is good pre-existing functional in-
sight. For example, the association of obesity-related gene
variants with a range of cardiometabolic traits has been in-
terpreted as evidence of the causal effect of adiposity
on these other risk factors.88 In other cases, however,
understanding of the functional relationships between the
myriad circulating biomarkers may not be deep, and it
may be difficult to exclude the possibility of horizontal
pleiotropy. Moreover, the extent of horizontal pleiotropy
may be underestimated because of the relatively modest
number of biomarker measures that are currently available
in epidemiological studies. The availability of new nuclear
magnetic resonance89 and mass spectrometry-based lipido-
mic and metabolomics analysis will soon allow more com-
prehensive assessment of horizontal pleiotropy. However,
such technologies also offer the enticing prospect of ascertain-
ing genetic instruments that instrument certain circulating
biomarkers more precisely. For example, the major blood
lipid fraction HDL-C actually represents the cholesterol con-
tent of a wide range of high-density lipoprotein particles
which each may have a different aetiological relationship
with other lipids and metabolites and with disease risk.
The variety of mechanisms by which horizontal plei-
otropy may arise are diminished the closer the biomarker
of interest lies (in a functional sense) to the genetic variant
which is acting as the instrument, hence the importance of
considering the nature of the biomarker of interest in an
MR analysis. According to the central dogma of molecular
biology, there is a unidirectional flow of information from
Figure 2. Mechanisms that may give rise to genetic pleiotropy and implications for MR analysis.
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genetic sequence variation through mRNA, protein and
thence through myriad downstream metabolic changes en
route to disease events. In essence, invariant sequence vari-
ation in DNA can encode downstream perturbations in the
transcriptome, proteome, metabolome and, in some in-
stances, disease risk, whereas these perturbations cannot,
to the best of our knowledge, alter DNA sequence.
Sequence variation can therefore be envisaged as produc-
ing a series of sequential perturbations of the transcrip-
tome, proteome and then metabolome. Proteins are the
most widely measured proximal circulating biomarkers of
interest for MR, separated from the genetic sequence only
by mRNA. Thus, when a protein biomarker is instru-
mented in an MR analysis by cis-acting variants in the
vicinity of the encoding gene, the likelihood of horizontal
pleiotropy is diminished, though it is still possible (e.g. by
alternative splicing of mRNA species; see Figure 2). If al-
ternative splicing of the mRNA, the presence of a local
miRNA encoding site and confounding by local and long-
range LD can be reliably excluded (e.g. based on widely
available, detailed, open access bioinformatic data), any
pleiotropy observed of a cis-SNP instrumenting its encoded
protein is more likely to be vertical than horizontal in ori-
gin. For this reason, MR analysis of protein biomarkers,
based on cis-SNPs, forms a privileged category of MR ana-
lysis—which we term ‘cis-MR’. Proteins form the targets
of most drugs, and several recent examples have demon-
strated that variants in genes encoding a drug target mimic
the mechanism-based consequences of modifying the same
target pharmacologically,90–92 confirming the validity of
the assumption of vertical pleiotropy and exemplifying the
utility of cis-MR. This observation is motivating a particu-
lar use of cis-MR: for drug target selection and character-
ization, with applications in drug development.93 SNPs
acting in cis could also be used as instruments to assess the
causal relevance for disease of epigenetic marks such as
DNA methylation94 or an even more proximal conse-
quence of sequence variation, mRNA level.23
Handling non-specific SNP associations in
MR analysis of non-protein biomarkers
The lack of specificity of genetic associations poses
greater difficulty when the biomarker of interest is not a
protein but a more distal biomarker, for example a lipid
particle (such as HDL-cholesterol) or a metabolite (e.g.
uric acid). In such cases, the distinction of cis-SNPs from
other categories of instrument is redundant. Moreover, be-
cause of limited functional understanding, it may be diffi-
cult to distinguish which of the several biomarkers
associated with an SNP lies proximal to the biomarker
of interest (and which could then influence disease
independently of it, violating one of the MR assumptions),
and which might lie distal to it on the causal pathway to
disease (Figure 2). In effect, under such circumstances it
can be difficult to distinguish horizontal from vertical plei-
otropy. How can the problem of non-specificity of the
available instruments be addressed in such situations?
Three complementary approaches are considered, which
harness the knowledge base of genome-wide associations
with disease biomarkers or recent methodological
developments.
Demonstration of the consistency of SNP-
biomarker-disease associations, regardless
of the genetic instrument employed
The first option is to compare the effect on disease risk of
genetic variants from different locations, each exhibiting a
shared association with the biomarker of interest but with
a different repertoire and pattern of effects on other bio-
markers. Here, causality for the biomarker of interest
would be inferred from a consistent association of the dif-
ferent instruments with both the biomarker and the disease
outcome. For example, SNPs in LDLR, PCSK9, APOE
and SORT131–33,69,70,95,96 have a distinct repertoire of ef-
fects on other biomarkers but all associate with LDL-chol-
esterol and also with the risk of CHD events, in proportion
to their effect of LDL-cholesterol, as carefully shown by
Ference and colleagues.97 This consistency provides strong
support for the causal role of LDL-cholesterol in the patho-
genesis of CHD (Supplementary figure 7, available as
Supplementary data at IJE online). By analogy, blood pres-
sure was confirmed to be a causal factor in CHD because
the many different blood pressure-lowering drugs tested in
RCTs (including diuretics, beta-blockers and calcium chan-
nel blockers) each reduced CHD risk despite different
mechanisms of action and different effects on other vari-
ables such as serum potassium, glucose and uric acid.
Multi-locus approaches
A second approach, whose use has been growing,88,98–100
is to derive a new genetic instrument that incorporates in-
formation from multiple loci. The instrument is composed
of SNPs selected from across the genome on the basis of a
genome-wide significant association with a trait of interest,
recognizing that some may exhibit associations with add-
itional biomarkers. The most conservative approach is to
select a single, strongly associated SNP from each locus;
however, approaches that incorporate several SNPs at each
associated locus where these are independent of one an-
other, to a whole genome approach, including SNPs whose
associations are below genome-wide levels of significance,
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have also been explored.101 The potential benefits are 2-
fold. The first is an increase in the variance in the trait of
interest explained by the genetic instrument to improve the
power of the MR analysis. The second is a possible dilu-
tional effect on pleiotropy, since SNPs selected on the basis
of an association with one biomarker should not systemat-
ically be associated with other biomarkers unless one or
more of these is in a related biological pathway. Under
those circumstances, it would not be possible to eliminate
pleiotropy entirely. The stability of the causal estimate
based on a multi-locus gene score, to the exclusion of sub-
sets of SNPs drawn at random, can be used as an adjunct
means to evaluate bias in the causal estimate that may arise
from the potential pleiotropic influence of a subset of
SNPs.
As discussed previously, SNPs associated with a particu-
lar biomarker tend to be distributed across many independ-
ent, biologically distinct loci (e.g. at least 36 loci associate
with LDL-cholesterol, 47 with HDL-cholesterol, 32 with
triglycerides30 and 23 with blood pressure26,37,38,102). It is
therefore possible to assign to each individual in a dataset a
score based either on a simple count of the number of trait-
raising alleles carried, or a score where the allele count is
weighted by the per-allele biomarker effect size.103 The set
of SNPs used for calculating such scores should have min-
imal redundancy so that each SNP is independent in its trait
effect, a simple approach is to select a single SNP from each
locus. In theory, associations that arise because of horizon-
tal pleiotropy at one locus should then be independent of
horizontal pleiotropic effects at other loci, and these smaller,
unsystematic horizontal pleiotropic associations should be
diluted relative to associations with the trait of interest.
Supplementary Figure 8 (available as Supplementary data at
IJE online) illustrates this effect using gene scores for HDL-
cholesterol and triglycerides in a sample of 5000 men and
women in the Whitehall II study.19 The scores were con-
structed using variants identified by one of the largest
GWAS of lipids published to date30 and are robustly associ-
ated with their cognate lipid fractions. In each case, the
score exhibits a considerably stronger association and
greater specificity than any individual SNP (Supplementary
Table 2, available as Supplementary data at IJE online),
which has also been demonstrated in an analysis of allele
scores for three clinically important biomarkers.101 A sim-
ple, unweighted score is justifiable if the component SNPs
all exhibit similar effect sizes. However, where a small num-
ber of loci have a dominant effect on the trait of interest (as
is the case with uric acid, for example), a weighted score
may be preferable. For weighted scores, the effect size
should ideally be calculated in a dataset independent from
that used for the MR analysis, to reduce bias as a conse-
quence of over-fitting.17
A further enhancement of the multi-locus approach
has been to use information from multiple SNPs but to
treat them as individual instrumental variables in a multi-
variable model, (see Palmer et al.17). Approaches that
allow the incorporation of summary genetic effect esti-
mates have also been developed, obviating the need to
have access to participant-level data.104,105 Techniques
have also been developed to accommodate the situation
where genotype-biomarker associations are available in
datasets distinct from, or only partially overlapping with,
those in which genotype-disease associations are
estimated.106
Despite the attraction of multi-locus approaches, it can
still prove difficult to develop a truly specific genetic in-
strument. For example, a multi-locus MR analysis of the
causal relevance of the three major lipid fractions was un-
able to identify instruments that were truly specific for
each lipid fraction, the development of specific instruments
for HDL-cholesterol and triglycerides being particularly
problematic. Approaches developed to deal with residual
pleiotropy include dropping the most pleiotropic SNPs
from the instrument (with a corresponding reduction in
power) or adjusting for residual pleiotropy in the analysis,
which requires access to participant-level data and is unsat-
isfying conceptually as it returns to a standard observa-
tional approach that it was hoped would be rendered
unnecessary by MR analysis.100,107,108
A further development, referred to as multivariable MR
analysis, allows for vertical or horizontal pleiotropic asso-
ciations among a pre-specified, measured set of risk fac-
tors.109–111 The assumptions of this approach are: that the
genetic variants used as instruments are associated with at
least one of a pre-specified set of risk factors, including the
risk factor(s) of primary interest, but not with any others
that might confound the association of the biomarker(s) of
interest with the disease outcome; and that none has an ef-
fect on disease outcome except through the set of pre-speci-
fied risk factors. The approach has been applied to dissect
the causal relevance of HDL-cholesterol and triglycerides
for CHD, using summary effect estimates from previous
GWAS.107 Although a clear advance, the approach can
only allow for biomarkers that have been measured in the
dataset. Horizontal pleiotropy due to unmeasured bio-
markers may still undermine causal interpretation as with
other types of MR analysis. The approach also focuses on
the causal relevance of the biomarker of interest on the dis-
ease outcome independent of other biomarkers, which may
underestimate the total causal effect in the preence of verti-
cal pleiotropy operating through another biomarker in the
pre-specified set.
To address the issue of unmeasured pleiotropy, Bowden
et al.112 recently reported that Egger regression, originally
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developed to quantify small-study bias in meta-analysis of
randomized trials, can be adapted and applied to provide an
unbiased estimate of the causal effect of a biomarker on dis-
ease outcome even in the presence of invalid genetic instru-
ments. Briefly, the unbiased causal effect of a biomarker on
disease outcome is estimated as the slope of the regression
line from a plot of the genotype-disease against genotype-
biomarker association for a set of variants selected for an as-
sociation with the biomarker of interest. By contrast to the
more usual two-stage least squares regression, the Egger re-
gression line is not constrained to pass through the origin.
The intercept of the line provides an estimate of the extent
of unmeasured pleiotropy. The approach is attractive but
suffers from a reduction in power compared with the other
methods. The reader is referred to the original paper for
more details. Sensitivity analysis, in which effect estimates
from standard two-stage least squares instrumental variable
analysis, multivariable MR analysis and MR-Egger are com-
pared, may help better judge the causal relevance of any
given biomarker. This approach is illustrated in a recent
MR analysis of uric acid in CHD.113
Importantly, regardless of the strengths and weaknesses
of each of these approaches, and bearing in mind there
may be no perfect solution to the problem of pleiotropic in-
struments in the MR analysis of non-protein biomarkers,
all approaches can be considered to be a substantial ad-
vance over non-genetic observation studies.
Reformulating the study question as a cis-
MR analysis
A third approach to addressing pleiotropy is to reframe the
research question so as to make a protein the primary ‘ex-
posure’ of interest. This allows the investigator to harness
the advantages of cis-MR. Since cis-acting regulatory vari-
ants in the vicinity of genes that influence mRNA and pro-
tein expression appear to be a consistent feature of the
genome, the genetic tools for cis-MR analyses of this type
should generally be available. Moreover, since more than
90% of drug targets are proteins,114 the analysis is likely
to have translational relevance, as cis-MR analysis has a
role as a means for drug target validation. For example, a
question on the causal role of HDL-cholesterol in CHD
could be reformulated as: ‘what is the likely therapeutic
benefit of targeting a specific protein (e.g. cholesteryl ester
transfer protein, CETP) that influences HDL-cholesterol
concentration?’ Though the causal relevance of HDL-C in
CHD is not directly answered by an analysis of this type
because SNPs in the CETP gene also influence other major
blood lipids and lipoproteins,30 these SNPs can help ad-
dress the specific and important question of whether
pharmacological modification of CETP to raise HDL-
cholesterol will help prevent CHD events.115,116
A guide to the selection of instruments for
MR analysis of disease-associated
biomarkers
Figure 3 summarizes some of the decisions to be made in
the selection of instruments for MR analyses of disease bio-
markers, based on the principles described in this review.
These serve as a guide, but we emphasize that each MR
analysis deserves thorough consideration on a case-by-case
basis, with due attention paid to any underlying biological
knowledge that may inform the design, analysis, reporting
and inferences drawn.
For example, variants in the IL6R gene are associated
with directionally opposite effects on CRP and interleukin-
6, which may confuse interpretation of MR analysis using
such instruments to evaluate the causal relevance of these
two biomarkers. Insight comes from a comparison of the
effect of pharmacological interleukin-6 receptor blockade
on these biomarkers. This clearly shows that such variants
mimic the effect of interleukin-6 receptor blockade and are
variants optimally suited to a cis-MR of this receptor, with
application in drug development.
The motivating factor for many MR analyses is the as-
sociation between a biomarker and a disease outcome de-
tected in an observational study. The next issue is
whether any genetic variant(s) associated with the bio-
marker of interest have been identified that might serve as
an instrument in an MR analysis. If the biomarker is a
protein and SNPs can be identified in the encoding gene
which influence its level or function, then a single locus
cis-MR may be possible, provided confounding by
LD and horizontal pleiotropy due to alternative splicing
or miRNA effects can be confidently excluded, and the
effect size is sufficiently large for an adequately powered
analysis.
If the biomarker is not a protein and SNPs from mul-
tiple independent loci contribute to its variance, a multi-
locus multi-instrument MR analysis may be possible, but
the instrument is more likely to be affected by horizontal
pleiotropy. The recent methodological advance of multi-
variable MR-Egger analysis may help deal with this.
Alternatively, it may be possible to refocus the research
question on variants influencing one or more of the pro-
teins encoded by the loci influencing the biomarker of
interest, that is reformulating the question as a cis-MR
analysis.
Regardless of the approach used, consideration should
be given to maximizing the sample size through the use of
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Figure 3. Illustrative guide to some of the key decisions in selecting instruments for MR analysis of disease biomarkers, based on the principles out-
lined in this review. The figure is intended to help plan a Mendelian randomization study of a disease-associated biomarker and should not be viewed
as an inflexible decision tree. For additional considerations and details, please refer to the main text.
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meta-analysis and the incorporation of public domain sum-
mary level estimates where possible.
Conclusions
MR offers novel opportunities for reliable causal infer-
ence within the framework of observational research de-
signs. The findings can provide insight into the
pathophysiology of complex disease and have transla-
tional relevance, including the prioritization of drug tar-
gets. The emerging genetic architecture of disease
biomarkers now allows more informed selection of gen-
etic variants for MR studies than was hitherto possible.
As the number of biomarker-associated variants grows,
selection of the most appropriate instruments for MR
analysis will become an increasingly important issue. We
have proposed a set of principles that should inform the
selection process to aid the design, analysis and interpret-
ation of MR studies.
Supplementary Data
Supplementary data are available at IJE online.
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